MG
NTLA icon

Michael Gelband’s Intellia Therapeutics NTLA Stock Holding History

Michael Gelband’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
65,592
+50,455
+333% +$706K 0.01% 1039
2026
Q1 		$194K Buy
+15,137
New +$193K ﹤0.01% 1385
2025
Q3 		– Sell
-58,609
Closed -$550K – 1871
2025
Q2 		$550K Sell
58,609
-29,043
-33% -$238K ﹤0.01% 1128
2025
Q1 		$623K Sell
87,652
-18,175
-17% -$184K 0.01% 1063
2024
Q4 		$1.23M Buy
105,827
+52,486
+98% +$819K 0.01% 881
2024
Q3 		$1.1M Buy
+53,341
New +$1.23M 0.01% 947
2024
Q2 		– Sell
-80,752
Closed -$2.22M – 1840
2024
Q1 		$2.22M Buy
80,752
+13,500
+20% +$375K 0.02% 659
2023
Q4 		$2.05M Buy
67,252
+35,816
+114% +$1.03M 0.01% 567
2023
Q3 		$994K Buy
31,436
+24,178
+333% +$938K 0.01% 971
2023
Q2 		$296K Buy
+7,258
New +$294K ﹤0.01% 1549
2023
Q1 		– Sell
-9,982
Closed -$348K – 2017
2022
Q4 		$348K Sell
9,982
-7,204
-42% -$343K 0.01% 1304
2022
Q3 		$962K Buy
17,186
+9,283
+117% +$576K 0.01% 1122
2022
Q2 		$409K Sell
7,903
-9,340
-54% -$474K 0.01% 1432
2022
Q1 		$1.25M Buy
+17,243
New +$1.46M 0.02% 1019
2021
Q4 		– Sell
-3,467
Closed -$465K – 2470
2021
Q3 		$465K Buy
+3,467
New +$525K 0.01% 1438
2021
Q1 		– Sell
-9,134
Closed -$497K – 2451
2020
Q4 		$497K Sell
9,134
-45,589
-83% -$1.66M ﹤0.01% 1257
2020
Q3 		$1.09M Buy
54,723
+15,841
+41% +$330K 0.02% 648
2020
Q2 		$817K Buy
+38,882
New +$661K 0.02% 844
2019
Q4 		– Sell
-13,089
Closed -$175K – 1774
2019
Q3 		$175K Buy
+13,089
New +$209K 0.01% 1158

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Michael Gelband's NTLA Position: Q2 2026 in Review

Michael Gelband increased its Intellia Therapeutics (NTLA) stake by 333% in Q2 2026, buying an estimated $706K and bringing the position to 65,592 shares worth $1.11M. The position accounts for 0.01% of the portfolio, ranked #1039.

Michael Gelband first reported a position in NTLA in Q3 2019 and has held it in 19 quarters since. The position peaked at $2.22M in Q1 2024. 326 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Michael Gelband held 65,592 shares of Intellia Therapeutics worth $1.11M as of Q2 2026.
  • Michael Gelband bought 50,455 Intellia Therapeutics shares in Q2 2026, an estimated $706K.
  • Intellia Therapeutics made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #1039 holding.
  • Michael Gelband first reported a position in Intellia Therapeutics in Q3 2019 and has held it in 19 quarters since.
  • Michael Gelband's Intellia Therapeutics position peaked at $2.22M in Q1 2024.
  • 326 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.